Name | sodium,(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylate |
---|---|
Synonyms | unii-94a7ufl2si |
Description | Enalapril (MK-421) sodium is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research[1][2]. |
---|---|
Related Catalog | |
In Vitro | Enalapril sodium (10-20 μM) has an antiarrhythmic effect in ultrafiltered PV sleeve preparation isolated from canine hearts which can inhibit EAD and DAD-induced activity[1]. Enalapril sodium (50 μM, 24 hours) inhibits the induction of apoptosis by patient serum only when used prior to treatment of HUVEC with Alzheimer's disease (AD) serum[2]. Pure Enalapril sodium has better thermal stability than pure Enalapril[3]. Apoptosis Analysis[2] Cell Line: Human umbilical vein ECs (HUVECs) Concentration: 50 μM Incubation Time: 24 hours Result: Inhibited the induction of apoptosis by patient serum. |
In Vivo | Enalapril sodium (intraperitoneal injection, 0.03 mg/kg, once, 1 hour) reduces infarct volume due to middle cerebral artery occlusion and lower or higher doses are ineffective in Male NMRI mice[4]. Animal Model: Male NMRI mice 20-40 g[4] Dosage: 0.03 mg/kg Administration: Intraperitoneal injection; once; 1 hour Result: Reduced the area of middle cerebral artery infarction in mice at 0.03 mg/kg. |
References |
Molecular Formula | C20H27N2NaO5 |
---|---|
Molecular Weight | 398.42900 |
Exact Mass | 398.18200 |
PSA | 98.77000 |
LogP | 0.59870 |